When journalist Jon Gluck learned he had multiple myeloma, doctors told him he had 18 months to live. That was 20 years ago. ...

Merck, as it prepares a new version of its cancer blockbuster Keytruda, gets a boost in its patent dispute with Halozyme ...

At the crossroads of innovation and equity, Josette Gbemudu and Merck are helping rewrite the narrative for breast cancer ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

US drug companies are increasingly licensing experimental medicines invented by Chinese firms. The recent deals could be ...

Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...

Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to ...

Bristol Myers Squibb BMY recently announced a strategic collaboration agreement with BioNTech BNTX for the global ...

Tango Therapeutics rebounds with a stronger pipeline, renewed focus on PRMT5 inhibitors, and key data ahead despite past ...

Around the world, Global Capability Centres are no longer just doing the work—they’re shaping it. At the final Bosch ...

Xiangxiang Ma, a partner of Anjie Broad Law Firm, explores the various ways in which a recent U.S. executive order on drug pricing is impacting Chinese pharmaceutical companies’ license-out model ...

CURE spoke with the principal investigator of a clinical trial evaluating a therapeutic vaccine for patients with advanced ...